Biotech Stocks: Resilience Amid AI Disruption

In the context of increasing discussions around artificial intelligence (AI) and its impact on various industries, the biotech sector has emerged as notably resistant to disruption. Analysts Josh Brown and Sean Russo from Ritholtz Wealth Management highlight this resilience, particularly focusing on two prominent companies: AbbVie (ABBV) and Amgen (AMGN). Their physical technology, which revolves around molecules and proteins, sets them apart from sectors more susceptible to AI-driven changes.

CNBC

Both AbbVie and Amgen have demonstrated strong financial performance recently. AbbVie, a biopharmaceutical company specializing in immunology, oncology, and neuroscience, reported record revenues of $61.2 billion in 2025, marking an 8.6% increase year-over-year. The company’s growth was particularly notable in its ex-Humira portfolio, which accelerated by 14.5% in the fourth quarter of 2025. As of early March 2026, AbbVie’s stock was trading around $230, maintaining a positive trend above its 50-day and 200-day moving averages.

CNBC

Amgen, which focuses on human therapeutics across various health domains, reported revenues of $36.8 billion in 2025, reflecting a 10% year-over-year increase. The company achieved record sales across 18 products, indicating robust market performance. As of March 2026, Amgen's stock was experiencing a pullback towards its 50-day moving average near $352, following a significant rally that began in November 2025.

CNBC

The biotech sector's unique infrastructure requirements—such as specialized facilities and regulatory approval processes—contribute to its stability against AI disruption. Brown and Russo emphasize that while AI enhances efficiency in drug discovery and treatment design, the foundational elements of biotech remain intact and resistant to rapid technological changes.

CNBC

For AbbVie, the stock's performance has been characterized by a consolidation phase, with critical support levels identified at the 50-day and 200-day moving averages. Analysts suggest that maintaining above these levels is crucial for sustaining the upward trend. Similarly, Amgen's recent price movements indicate a need for careful monitoring, particularly as it approaches key support zones.

CNBC

Despite the positive outlook for AbbVie and Amgen, some market analysts caution against potential volatility. The biotech sector's reliance on regulatory approvals and patent exclusivity can introduce risks that may affect stock performance. Additionally, the broader market dynamics influenced by economic conditions and investor sentiment could impact these companies' trajectories.

CNBC

• “Drug manufacturing requires specialized facilities, logistics and biologic infrastructure that can't be vibe-coded overnight.” — Josh Brown, Ritholtz Wealth Management

CNBC

• “As long as the stock holds that level, the consolidation remains constructive and the broader uptrend is intact.” — Sean Russo, Ritholtz Wealth Management

CNBC

• “A decisive break below the 200-day would represent the first meaningful technical damage and suggest the range is resolving lower rather than preparing for a breakout above the recent highs in the $240 area.” — Sean Russo, Ritholtz Wealth Management

CNBC

The biotech sector, exemplified by AbbVie and Amgen, showcases resilience in the face of AI advancements. With strong financial performances and a unique operational framework, these companies are positioned to navigate the complexities of the evolving market landscape. Investors are advised to remain vigilant regarding technical indicators and market conditions as they assess opportunities within this sector.

CNBC